Cancer Genetics
Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare
Sophia, which will trade on the Nasdaq, seeks to raise $100 million in an IPO, and separately announced a partnership with GE Healthcare.
In Brief This Week: Danaher, Guardant Health, Invitae, Yourgene Health, and More
News items for the in vitro diagnostics industry for the week of March 29, 2021.
Interpace Diagnostics Reports 33 Percent Q3 Revenue Growth; Changes Name to Interpace Biosciences
The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.
Cancer Genetics Announces 1-for-30 Reverse Stock Split
The firm said it is executing the reverse stock split with the aim of increasing its stock price to satisfy a minimum bid price requirement for continued listing.
Cancer Genetics Posts 15 Percent Rise in Q2 Revenues
The revenues come entirely from CGI's discovery services as its divested biopharma services and clinical lab units were considered discontinued operations.
May 21, 2019
Cancer Genetics Q1 Revenues Fall 11 Percent
Apr 16, 2019
Cancer Genetics Q4 Revenues Down 9 Percent
Jan 10, 2019
Cancer Genetics Targets $3M in Public Offering
Nov 20, 2018
Cancer Genetics Q3 Revenues Fall 26 Percent
Sep 26, 2018
Cancer Genetics, Agilent Sign FISH Probe Supply Deal
Sep 18, 2018
Cancer Genetics, NovellusDx Sign Merger Agreement
Aug 14, 2018
Cancer Genetics Q2 Revenues Rise 7 Percent
May 15, 2018
Cancer Genetics Q1 Revenues Up 10 Percent
Apr 26, 2018
Apr 2, 2018